| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H21N2O5.Na |
| Molecular Weight | 344.3381 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCC1=CC=CC(CC)=C1NC(=O)CN(CC(O)=O)CC([O-])=O
InChI
InChIKey=PHLQJWHZXVGNDF-UHFFFAOYSA-M
InChI=1S/C16H22N2O5.Na/c1-3-11-6-5-7-12(4-2)16(11)17-13(19)8-18(9-14(20)21)10-15(22)23;/h5-7H,3-4,8-10H2,1-2H3,(H,17,19)(H,20,21)(H,22,23);/q;+1/p-1
Etifenin is a diagnostic radiopharmaceutical for the liver function assessment. It is used for hepatobiliary function scintigraphy where there is the following suspicion: Acute cholecystitis; Chronic gall duct changes; Occlusion of ductus choledochus; Congenital aberrances of the gall duct system such as atresia; Provision of evidence of bile leak; For differential diagnosis of intrahepatic growth (suspicion of focal nodular hyperplasia versus suspicion of liver cell cancer). The diagnostic significance in liver cancer is rather marginal compared to other imaging procedures. No information on adverse reactions after intravenous injection of the ready-to-use solution is available.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Single injection after reconstitution with sodium [99mTc]per-technetate solution. Adults with a normal liver function will receive an activity of 150 MBq and up to 420 MBq if they have a disturbed liver function with serum bilirubin values >25 mol/l. Patients should not eat during at least 2 hours or better 4 hours prior to administration.
Route of Administration:
Intravenous
The HIDA/saline and HIDA/plasma mixtures were incubated at 37°C for 15 min, then a 0.5 ml aliquot of each mixture was applied to the top of its respective Sephadex column. Incubation in plasma had no effect on the chromatogram of Etifenin. Results indicate that, under the conditions described, Etifenin is not a protein(albumin)-bound agent.
SUBSTANCE RECORD
